


Berotalstat

Cat. No.:	HY-109127
CAS No.:	1809010-50-1
Molecular Formula:	C ₃₀ H ₂₆ F ₄ N ₆ O
Molecular Weight:	562.56
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (177.76 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	1.7776 mL	8.8879 mL	17.7759 mL
			5 mM	0.3555 mL	1.7776 mL	3.5552 mL
			10 mM	0.1778 mL	0.8888 mL	1.7776 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 8.5 mg/mL (15.11 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Berotalstat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotalstat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE ^{[1][2]} .
IC ₅₀ & Target	Plasma kallikrein ^[1]

REFERENCES

[1]. Zuraw B, et al. Oral once-daily berotalstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. *J Allergy Clin Immunol.* 2020;S0091-6749(20)31484-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA